Where Does Unity Biotechnology Inc. (UBX) Rank When It Comes To Price-To-Earnings Ratio?


Unity Biotechnology Inc. (NASDAQ:UBX) traded with a subtraction of -$0.01 to $0.42 on Thursday, a downside of -2.09 percent. An average of 1,124,158 shares of common stock have been traded in the last five days. There was a fall of -$0.0660 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 2,082,174 shares traded, while the 50-day average volume stands at 4,780,716.

UBX stock has decreased by -30.26% in the last month. The company shares reached their 1-month lowest point of $0.4110 on 09/22/22. With the stock rallying to its 52-week high on 01/04/22, shares of the company touched a low of $0.42 and a high of $3.64 in 52 weeks. It has reached a new high 2 times so far this year and lost -70.86% or -$1.0450 in price. In spite of this, the price is down -88.56% from the 52-week high.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Insider Transactions

8 days have passed since Unity Biotechnology Inc. (UBX) last reported insider trading activity. Ghosh Anirvan, who is Chief Executive Officer, most recently acquired $13,706 shares at $0.48 per share on Sep 14. In this transaction, the insider spent $6,579. Chief Medical Officer, Dananberg Jamie, disposed of 10,923 shares at a price of $0.48 on Sep 14. The insider now owns more than $5,243 worth of shares. Prior to that, Chief Executive Officer Ghosh Anirvan went on to Sale 10,446 shares at $0.67 each on Aug 01. An amount of $6,999 was transacted.

Valuation Metrics

Unity Biotechnology Inc. (UBX) stock’s beta is 0.71. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 12.33, the price-to-book (PB) ratio at 0.73.

Financial Health

The quick ratio of Unity Biotechnology Inc. for the three months ended June 29 was 4.10, and the current ratio was 4.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.32 and a total debt to equity ratio of 0.50 for the quarter ending June 29.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Unity Biotechnology Inc.’s return on assets was -51.40%.

Earnings Surprise

For the three-month period that ended June 29, Unity Biotechnology Inc. had $45.07 million in cash and short-term investments compared to $12.67 million in total debt. The company posted a net income of -$13.14 million in the quarter, while revenues of -$18.92 million were shrunk -35.69%. The analyst consensus anticipated Unity Biotechnology Inc.’s latest quarter earnings to come in at -$0.28 per share, but it turned out to be -$0.19, a 32.10% surprise. For the quarter, EBITDA amounted to -$12.26 million. Shareholders own equity worth $69.65 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Unity Biotechnology Inc. (UBX) price momentum. RSI 9-day as of the close on 21 September was 29.39%, suggesting the stock is oversold, with historical volatility in this time frame at 21.79%.

As of today, UBX’s price is $0.4411 -13.72% or -$0.0660 from its 5-day moving average. UBX is currently trading -28.45% lower than its 20-day SMA and -54.40% lower than its 100-day SMA. However, the stock’s current price level is -41.37% below the SMA50 and -75.44% below the SMA200.

The stochastic %K and %D were 11.20% and 20.96%, respectively, and the average true range (ATR) was 0.0440. With the 14-day stochastic at 3.37% and the average true range at 0.0619, the RSI (14) stands at 35.87%. The stock has reached -0.0338 on the 9-day MACD Oscillator while the 14-day reading was at -0.0369.

Analyst Ratings

ROTH Capital upgraded Unity Biotechnology Inc. (NASDAQ: UBX) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Unity Biotechnology Inc. (UBX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell UBX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 6 others rate it as a “buy”.

What is UBX’s price target for the next 12 months?

Analysts predict a range of price targets between $3.00 and $12.00, with a median target of $8.00. Taking a look at these predictions, the average price target given by analysts for Unity Biotechnology Inc. (UBX) stock is $7.83.


Please enter your comment!
Please enter your name here